

# Hepatitis C Follow-Up Information and Website Resources

## Background

On June 1, 2023, HHSC notified pharmacies, prescribers, and stakeholders of changes to the quantity limits on direct-acting antiviral (DAA) drugs for treating Hepatitis C.

## Key Details

HHSC now has additional resources to share with MCOs to help spread awareness among members and providers of the treatment opportunity in Medicaid.

Included with this notice are client-facing notices, in English and Spanish, MCOs can use as outreach to your members. Please continue contacting your members and providers about the available diagnosis and treatment opportunities.

Additionally, VDP recently published a web page regarding our Hepatitis C Virus (HCV) initiative. The page includes links to client and prescriber resources on testing, Mavyret, HHSC's partnership with AbbVie, and more. MCOs are encouraged to share this with members and providers.

## Resources

- <https://www.txvendordrug.com/formulary/hepatitis-c>
- <https://www.hhs.texas.gov/services/health/prevention/hepatitis-c-treatment>
- [Hepatitis C Notice - English](#)
- [Hepatitis C Notice - Spanish](#)